<?xml version='1.0' encoding='utf-8'?>
<document id="27901310"><sentence text="Topical Antimycotics for Oral Candidiasis in Warfarin Users." /><sentence text="Treatment for oral candidiasis in warfarin users may be complicated by drug-drug interactions (DDIs) between warfarin and topically applied antimycotics" /><sentence text=" However, current knowledge of these putative DDIs is merely based on case series" /><sentence text=" We therefore performed a cohort cross-over study with the objective to evaluate the potential DDIs between warfarin and miconazole oral gel or nystatin oral solution"><entity charOffset="121-131" id="DDI-PubMed.27901310.s4.e0" text="miconazole" /><entity charOffset="144-152" id="DDI-PubMed.27901310.s4.e1" text="nystatin" /><pair ddi="false" e1="DDI-PubMed.27901310.s4.e0" e2="DDI-PubMed.27901310.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27901310.s4.e0" e2="DDI-PubMed.27901310.s4.e1" /></sentence><sentence text=" The cohort consisted of individuals using warfarin in the period of 1998-2012 (n â‰ˆ 7400)" /><sentence text=" We collected data on cohort members' measurements of the international normalized ratio (INR) from a clinical database, and obtained information on their use of topically applied miconazole and nystatin from a regional prescription register"><entity charOffset="180-190" id="DDI-PubMed.27901310.s6.e0" text="miconazole" /><entity charOffset="195-203" id="DDI-PubMed.27901310.s6.e1" text="nystatin" /><pair ddi="false" e1="DDI-PubMed.27901310.s6.e0" e2="DDI-PubMed.27901310.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27901310.s6.e0" e2="DDI-PubMed.27901310.s6.e1" /></sentence><sentence text=" Potential DDIs were assessed by comparing INR values before and after initiation of an antimycotic drug" /><sentence text=" Among 17 warfarin users exposed to miconazole oral gel, the mean INR increased from 2"><entity charOffset="36-46" id="DDI-PubMed.27901310.s8.e0" text="miconazole" /></sentence><sentence text="5 (95% CI: 2" /><sentence text="1-2" /><sentence text="8) to 3" /><sentence text="8 (95% CI: 2" /><sentence text="8-4" /><sentence text="8) after exposure, corresponding to a mean INR increase of 1" /><sentence text="4 (95% CI: 0" /><sentence text="3-2" /><sentence text="4)" /><sentence text=" Among 30 warfarin users exposed to nystatin oral solution, the mean INR was 2"><entity charOffset="36-44" id="DDI-PubMed.27901310.s18.e0" text="nystatin" /></sentence><sentence text="7 (95% CI: 2" /><sentence text="3-3" /><sentence text="1) before and 2" /><sentence text="5 (95% CI: 2" /><sentence text="2-2" /><sentence text="9) after exposure" /><sentence text=" In conclusion, we found evidence supporting a clinically relevant drug-drug interaction between warfarin and miconazole oral gel"><entity charOffset="110-120" id="DDI-PubMed.27901310.s25.e0" text="miconazole" /></sentence><sentence text=" In contrast, we did not find any indication of an interaction between warfarin and nystatin oral solution"><entity charOffset="84-92" id="DDI-PubMed.27901310.s26.e0" text="nystatin" /></sentence><sentence text=" Nystatin rather than miconazole should be preferred when treating warfarin users for oral candidiasis"><entity charOffset="1-9" id="DDI-PubMed.27901310.s27.e0" text="Nystatin" /><entity charOffset="22-32" id="DDI-PubMed.27901310.s27.e1" text="miconazole" /><pair ddi="false" e1="DDI-PubMed.27901310.s27.e0" e2="DDI-PubMed.27901310.s27.e0" /><pair ddi="false" e1="DDI-PubMed.27901310.s27.e0" e2="DDI-PubMed.27901310.s27.e1" /></sentence><sentence text="" /></document>